Themis Medicare Limited has informed the Exchange regarding Change in Director(s) of the company.
THEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Themis Medicare's board approved the unaudited Q1 FY26 results showing a sharp reversal — standalone net loss of Rs. 1,537.37 lakhs versus a profit of Rs. 1,871.47 lakhs in Q1 FY25, with revenue falling ~21% YoY to Rs. 9,757.77 lakhs. The company also appointed Ms. Neha Thakore as an Additional Non-Executive Woman Independent Director for 5 years and Mr. Viraj Save as Executive President – Sales & Marketing. The board withdrew the proposed merger with Gujarat Themis Biosyn Limited after GTBL decided to stay independent, and noted the strike-off of UK subsidiary Carpo Medicals Limited, leading to an exceptional loss of Rs. 129.39 lakhs. A record date of September 5, 2025 was set for the final dividend for FY25.
Weak quarterly performance with a swing to losses and a sharp revenue decline is likely to weigh on the stock in the short term. The withdrawn merger removes a potential growth catalyst, but the dividend record date offers some near-term support to shareholders.